Novo Nordisk is highlighted for its deep dominance in the rapidly growing diabetes and obesity markets, supported by a strong product portfolio, consistent revenue growth, and ongoing innovation.
Source Post
Tom Lee: “This Is Why The Market Won’t Fall Anymore” (3 Insanely Cheap Stocks To Buy Now)
Apr 15, 2026
The creator discusses Tom Lee's bullish market outlook, suggesting the market bottom is in due to exhausted selling pressure and repositioning. The video then highlights three undervalued stocks: AbbVie (ABBV) for its strong cash flow and transitioning drug portfolio, Novo Nordisk (NVO) for its dominance in the diabetes and obesity market, and Verizon (VZ) for its essential infrastructure, consistent revenue, and attractive dividend yield. The creator emphasizes that these companies are currently underestimated by the market, presenting opportunities for long-term investors.
Linked Mentions
Tickers discussed in this post
AbbVie is presented as a compelling investment due to its strong cash flow, successful transition from Humira with new drugs like Skyrizi and Rinvoq, a compelling dividend yield, and an undervalued stock price.